{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T19:38:53Z","timestamp":1794685133461,"version":"4.9.1"},"reference-count":20,"publisher":"American Society of Hematology","issue":"3","license":[{"start":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T00:00:00Z","timestamp":1703116800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,2,13]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>18F-fluorodeoxyglucose-positron emission tomography (FDG-PET) is a valuable prognostic tool in modern lymphoma care. In this study, we explored the use of quantitative FDG-PET parameters in predicting the histology of suspected relapsed or refractory (R\/R) lymphoma. We retrospectively analyzed 290 FDG-PET scans performed for suspected R\/R lymphoma. FDG-PET parameters measured were maximum and mean standardized uptake value (SUVMax and SUVMean), total metabolic tumor volume, and total lesion glycolysis (TLG). Receiver operating characteristic curve analysis was used to obtain the optimal thresholds that best discriminate (1) benign vs R\/R lymphoma, (2) indolent vs aggressive non-Hodgkin lymphoma (NHL), and (3) aggressive transformation of indolent NHL. We found that although all 4 FDG-PET parameters discriminated R\/R lymphoma from benign histology, TLG was the best performing parameter (optimal cut-off \u2265245, sensitivity 63%, specificity 86%, positive predictive value [PPV] 97%, negative predictive value [NPV] 30%, area under the curve [AUC] 0.798, and P &amp;lt; .001). SUVMax discriminated aggressive from indolent NHL with modest accuracy (optimal threshold \u226515, sensitivity 46%, specificity 79%, PPV 82%, NPV 38%, AUC 0.638, and P &amp;lt; .001). In patients with a prior diagnosis of indolent NHL, SUVMax was a modest predictor of transformation (optimal cut-off \u226512, sensitivity 71%, specificity 61%, PPV 50%, NPV 78%, AUC 0.676, and P .006). Additionally, SUVMax \u226525 and an increase in SUVMax (\u0394SUVMax) from baseline \u2265150% were highly specific (96% and 94%, respectively). These FDG-PET thresholds can aid in identification of suspected R\/R lymphoma cases with higher likelihood of R\/R disease and aggressive transformation of indolent NHL, guiding the necessity and urgency of biopsy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023011566","type":"journal-article","created":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T16:07:20Z","timestamp":1703174840000},"page":"736-745","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":10,"title":["Utility of FDG-PET in predicting the histology of relapsed or refractory lymphoma"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3925-4302","authenticated-orcid":false,"given":"Shin Hnin","family":"Wai","sequence":"first","affiliation":[{"name":"1Austin Health, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sze Ting","family":"Lee","sequence":"additional","affiliation":[{"name":"1Austin Health, Melbourne, VIC, Australia"},{"name":"2Olivia Newton-John Cancer Research Institute, Melbourne, VIC, Australia"},{"name":"3Department of Medicine, Melbourne University, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5977-907X","authenticated-orcid":false,"given":"Edward R. Scheffer","family":"Cliff","sequence":"additional","affiliation":[{"name":"1Austin Health, Melbourne, VIC, Australia"},{"name":"4Program on Regulation, Therapeutics and Law, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2823-9107","authenticated-orcid":false,"given":"Michael","family":"Bei","sequence":"additional","affiliation":[{"name":"5Western Health, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiwoo","family":"Lee","sequence":"additional","affiliation":[{"name":"5Western Health, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0376-2559","authenticated-orcid":false,"given":"Eliza A.","family":"Hawkes","sequence":"additional","affiliation":[{"name":"1Austin Health, Melbourne, VIC, Australia"},{"name":"2Olivia Newton-John Cancer Research Institute, Melbourne, VIC, Australia"},{"name":"6School of Public Health & Preventative Medicine, Monash University, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4006-2380","authenticated-orcid":false,"given":"Geoffrey","family":"Chong","sequence":"additional","affiliation":[{"name":"1Austin Health, Melbourne, VIC, Australia"},{"name":"2Olivia Newton-John Cancer Research Institute, Melbourne, VIC, Australia"},{"name":"3Department of Medicine, Melbourne University, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,1,31]]},"reference":[{"issue":"5","key":"2024021217145849100_bib1","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/bjh.15412","article-title":"How I manage patients with relapsed\/refractory diffuse large B cell lymphoma","volume":"182","author":"Gisselbrecht","year":"2018","journal-title":"Br J Haematol"},{"issue":"16","key":"2024021217145849100_bib2","doi-asserted-by":"crossref","first-page":"4208","DOI":"10.1182\/blood-2010-09-288373","article-title":"How I treat relapsed and refractory Hodgkin lymphoma","volume":"117","author":"Kuruvilla","year":"2011","journal-title":"Blood"},{"issue":"26","key":"2024021217145849100_bib3","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1200\/JCO.2012.48.3990","article-title":"Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa\/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource","volume":"31","author":"Link","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2024021217145849100_bib4","doi-asserted-by":"crossref","first-page":"e0210224","DOI":"10.1371\/journal.pone.0210224","article-title":"Prognostic value of baseline metabolic tumor volume and total lesion glycolysis in patients with lymphoma: a meta-analysis","volume":"14","author":"Guo","year":"2019","journal-title":"PLoS One"},{"issue":"2","key":"2024021217145849100_bib5","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/bjh.18016","article-title":"Pre-treatment total metabolic tumour volumes in lymphoma: Does quantity matter?","volume":"197","author":"El-Galaly","year":"2022","journal-title":"Br J Haematol"},{"issue":"16","key":"2024021217145849100_bib6","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1182\/blood.2019003526","article-title":"High total metabolic tumor volume at baseline predicts survival independent of response to therapy","volume":"135","author":"Vercellino","year":"2020","journal-title":"Blood"},{"issue":"4","key":"2024021217145849100_bib7","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/ejh.13684","article-title":"Predicting primary treatment failure using interim FDG-PET scanning in diffuse large B-cell lymphoma","volume":"107","author":"Wight","year":"2021","journal-title":"Eur J Haematol"},{"issue":"5","key":"2024021217145849100_bib8","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1080\/10428194.2020.1855341","article-title":"SUV(max)-based assessment of PET response shows a superior specificity to Deauville criteria for predicting recurrence in Hodgkin's lymphoma","volume":"62","author":"Texte","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"2024021217145849100_bib9","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1080\/10428194.2023.2239404","article-title":"FDG-PET\/CT response assessment with qualitative Lugano criteria outperforms change in SUVmax as a predictive biomarker in frontline treatment of mantle cell lymphoma","volume":"64","author":"Russler-Germain","year":"2023","journal-title":"Leuk Lymphoma"},{"issue":"18","key":"2024021217145849100_bib10","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1182\/blood-2013-11-536169","article-title":"Correlation between FDG\/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia","volume":"123","author":"Falchi","year":"2014","journal-title":"Blood"},{"issue":"15","key":"2024021217145849100_bib11","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1182\/blood.2019001091","article-title":"Baseline SUVmax did not predict histological transformation in follicular lymphoma in the phase 3 GALLIUM study","volume":"135","author":"Mir","year":"2020","journal-title":"Blood"},{"key":"2024021217145849100_bib17","author":"Swerdlow","year":"2017","edition":"Revised 4th ed."},{"issue":"5","key":"2024021217145849100_bib12","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/bjh.14831","article-title":"Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group","volume":"178","author":"Alonso-\u00c1lvarez","year":"2017","journal-title":"Br J Haematol"},{"issue":"34","key":"2024021217145849100_bib13","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1200\/JCO.18.00138","article-title":"Risk factors for transformation to higher-grade lymphoma and its impact on survival in a large cohort of patients with marginal zone lymphoma from a single institution","volume":"36","author":"Alderuccio","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"2024021217145849100_bib14","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41408-019-0269-6","article-title":"Enhancement of the Follicular Lymphoma International Prognostic Index (FLIPI) with lymphopenia (FLIPI-L): a predictor for overall survival and histologic transformation","volume":"9","author":"Yang","year":"2020","journal-title":"Blood Cancer J"},{"issue":"1","key":"2024021217145849100_bib15","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1080\/10428194.2020.1821010","article-title":"A\u00a0low lymphocyte-to-monocyte ratio is an independent predictor of poorer survival and higher risk of histological transformation in follicular lymphoma","volume":"62","author":"Mozas","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"23","key":"2024021217145849100_bib16","doi-asserted-by":"crossref","first-page":"8864","DOI":"10.1002\/cam4.3501","article-title":"Transformation Scoring System (TSS): a new assessment index for clinical transformation of follicular lymphoma","volume":"9","author":"Shichijo","year":"2020","journal-title":"Cancer Med"},{"issue":"9","key":"2024021217145849100_bib18","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1093\/annonc\/mdp030","article-title":"High SUV uptake on FDG-PET\/CT predicts for an aggressive B-cell lymphoma in a prospective study of primary FDG-PET\/CT staging in lymphoma","volume":"20","author":"Ngeow","year":"2009","journal-title":"Ann Oncol"},{"issue":"21","key":"2024021217145849100_bib19","doi-asserted-by":"crossref","first-page":"4643","DOI":"10.1200\/JCO.2005.12.072","article-title":"Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma","volume":"23","author":"Sch\u00f6der","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"2024021217145849100_bib20","doi-asserted-by":"crossref","first-page":"471","DOI":"10.3324\/haematol.12013","article-title":"Investigation of FDG-PET\/CT imaging to guide biopsies in the detection of histological transformation of indolent lymphoma","volume":"93","author":"Bodet-Milin","year":"2008","journal-title":"Haematologica"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/3\/736\/2212975\/blooda_adv-2023-011566-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/3\/736\/2212975\/blooda_adv-2023-011566-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T17:15:31Z","timestamp":1707758131000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/3\/736\/506681\/Utility-of-FDG-PET-in-predicting-the-histology-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,31]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,2,13]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023011566","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,31]]}}}